^
    Back
    Association details:
    Biomarker:EGFR C797S
    Cancer:Non Small Cell Lung Cancer
    Drug:JIN-A02 (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC

    Excerpt:
    ...Advanced NSCLC subjects who are positive to EGFR mutant C797S or T790M 2....
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    IASLC-WCLC 2022
    Title:

    MA07.08 - JIN-A02, a Highly Effective 4th Generation EGFR-TKI, Targeting EGFR C797S Triple Mutation in NSCLC

    Published date:
    07/12/2022
    Excerpt:
    These preclinical studies demonstrated that JIN-A02 is a potential best-in-class fourth-generation EGFR TKI with high potency and selectivity. JIN-A02 showed robust activities against EGFR C797S mutation including single and double EGFR mutations. It was also effective against L718Q, for which there are currently no treatment alternatives.